AJCN North Carolina Research Campus
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spiers, P. A.
Right arrow Articles by Schomer, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spiers, P. A.
Right arrow Articles by Schomer, D. L.
Agricola
Right arrow Articles by Spiers, P. A.
Right arrow Articles by Schomer, D. L.

American Journal of Clinical Nutrition, Vol 68, 531-537, Copyright © 1998 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Aspartame: neuropsychologic and neurophysiologic evaluation of acute and chronic effects

PA Spiers, L Sabounjian, A Reiner, DK Myers, J Wurtman and DL Schomer
Clinical Research Center, Massachusetts Institute of Technology, Cambridge 02139, USA.

BACKGROUND: Neurobehavioral symptoms have been reported anecdotally with aspartame. OBJECTIVE: This study sought to determine whether aspartame can disrupt cognitive, neurophysiologic, or behavioral functioning in normal individuals. DESIGN: Forty-eight healthy volunteers completed a randomized, double-blind, placebo-controlled, crossover study. The first month was aspartame free. Subjects then consumed sodas and capsules with placebo, aspartame, or sucrose for 20 d each. Order was randomized and subjects were assigned to either a high- (45 mg x kg body wt(-1) x d(-1)) or low- (15 mg x kg body wt(-1) x d(-1)) dose aspartame group. Neuropsychologic and laboratory testing was done on day 10 of each treatment period to determine possible acute effects and on day 20 for possible chronic effects. RESULTS: Plasma phenylalanine concentrations increased significantly during aspartame treatment. Neuropsychologic results; adverse experiences; amino acid, insulin, and glucose values; and electroencephalograms were compared by sex and by treatment. No significant differences were found for any dependent measure. CONCLUSION: Large daily doses of aspartame had no effect on neuropsychologic, neurophysiologic, or behavioral functioning in healthy young adults.


This article has been cited by other articles:


Home page
 Hum Exp ToxicolHome page
A Vences-Mejia, N Labra-Ruiz, N Hernandez-Martinez, V Dorado-Gonzalez, J Gomez-Garduno, I Perez-Lopez, R Nosti-Palacios, R C. Carranza, and J. Espinosa-Aguirre
The Effect of Aspartame on Rat Brain Xenobiotic-Metabolizing Enzymes
Human and Experimental Toxicology, August 1, 2006; 25(8): 453 - 459.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by The American Society for Nutrition